Millennium Management’s Cytokinetics CYTK Stock Holding History

Millennium Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.11M	Buy	+107,900	New	+$6.86M	﹤0.01%	2551
2024 Q2	–	Sell	-18,300	Closed	-$1.28M	–	5992
2024 Q1	$1.28M	Sell	18,300 -39,200	-68%	-$3.03M	﹤0.01%	4089
2023 Q4	$4.8M	Buy	+57,500	New	+$2.08M	﹤0.01%	2823
2021 Q3	–	Sell	-91,800	Closed	-$1.82M	–	6851
2021 Q2	$1.82M	Buy	91,800 +45,200	+97%	+$1.06M	﹤0.01%	4077
2021 Q1	$1.08M	Buy	+46,600	New	+$995K	﹤0.01%	4140

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management's CYTK Position: Q1 2026 in Review

Millennium Management reduced its Cytokinetics (CYTK) stake by 57% in Q1 2026, selling an estimated $8.1M and leaving 97,959 shares worth $6.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2651.

Millennium Management first reported a position in CYTK in Q2 2013 and has held it in 48 quarters since. The position peaked at $100M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Millennium Management held 97,959 shares of Cytokinetics worth $6.46M as of Q1 2026.
Millennium Management sold 127,497 Cytokinetics shares in Q1 2026, an estimated $8.1M.
Cytokinetics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2651 holding.
Millennium Management first reported a position in Cytokinetics in Q2 2013 and has held it in 48 quarters since.
Millennium Management's Cytokinetics position peaked at $100M in Q4 2023.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.